ArticleCommunications medicine2025
Greater value add from electronic health records than polygenic risk scores for predicting myocardial infarction in machine learning.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Artificial intelligence approaches to predicting treatment non-adherence in chronic diseases: a narrative review.Frontiers in digital health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPolygenic risk scores (PRSs) are increasingly being used to predict disease risk from genetic data. While promising in research, their clinical utility-especially when combined with non-genetic (NG) data such as lab results, physical measurements, and diagnostic history-remains uncertain. Myocardial infarction (MI), a leading cause of morbidity and mortality, is a key use case for assessing the incremental value of PRSs in risk models.
methodsUsing UK Biobank data, we evaluated the added value of PRSs for 10-year MI risk prediction. We trained models with NG data alone and in combination with PRSs, varying model complexity and the NG feature space. Two modeling frameworks were used: logistic regression and a neural network. NG data was defined using two feature sets: NG1, which included established MI risk factors from structured fields; and NG2, a high-dimensional dataset derived from millions of diagnostic codes across five linked UK Biobank electronic health records (EHR) datasets combined with NG1 features. NG2 was generated using a deep representation learning approach that produced low-dimensional embeddings capturing latent medical concepts and disease co-occurrence patterns. Each model was trained with and without PRSs and evaluated using metrics such as the area under the ROC curve (AUC).
resultsPRSs add minimal predictive value when used alone. In contrast, diagnostic data from EHRs significantly improve performance. The best results are achieved using a multimodal neural network combining NG1, NG2, and PRSs.
conclusionsPRSs provide limited standalone utility for MI prediction compared to detailed diagnostic data. Their clinical value likely lies in integration with EHR-based models. Future work should focus on multi-modal approaches that contextualize PRS information within broader clinical data.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.